Thanks for clarifying this. Someone with a medical background or understanding of clinical evidence needed to clarify the relevance of an anecdotal case to practice guidelines (and thus adoption of a new therapy).
I noticed on the NAN threads that investors (perhaps laypeople) are excited about endoscopy-related complications, which is entirely separate from ultrasound technologies!
Dramatic response to SIRT, page-5
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
-0.003(1.39%) |
Mkt cap ! $75.34M | |||
| Open | High | Low | Value | Volume |
| 17.8¢ | 17.8¢ | 17.5¢ | $8.638K | 48.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 11236354 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1327703 | 33 |
View Market Depth
| Last trade - 15.52pm 09/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |